Chlamydophila pneumoniae 83558 Chlamydophila pneumoniae is a small bacterium (0.2 to 1 micrometer) that undergoes several transformations during its life cycle. It exists as an elementary body (EB) in between hosts. The EB is not biologically active but is resistant to environmental stresses and can survive outside of a host for a limited time. The EB travels from an infected person to the lungs of a non-infected person in small droplets and is responsible for infection. Once in the lungs, the EB is taken up by cells in a pouch called an endosome by a process called phagocytosis. However, the EB is not destroyed by fusion with lysosomes as is typical for phagocytosed material. Instead, it transforms into a reticulate body and begins to replicate within the endosome. The reticulate bodies must utilize some of the host's cellular machinery to complete its replication. The reticulate bodies then convert back to elementary bodies and are released back into the lung, often after causing the death of the host cell. The EBs are thereafter able to infect new cells, either in the same organism or in a new host. Thus, the life cycle of C. pneumoniae is divided between the elementary body, which is able to infect new hosts but can not replicate, and the reticulate body ,which replicates but is not able to cause new infection (Wiki: Chlamydophila pneumoniae). Pneumonia In addition to infecting humans, C. pneumoniae also infects and causes disease in Koalas, emerald tree boa (Corallus caninus), iguanas, chameleons, frogs, and turtles (Wiki: Chlamydophila pneumoniae). Chlamydophila pneumoniae is a species of Chlamydophila bacteria[1][2][3] that infects humans and is a major cause of pneumonia. C. pneumoniae has a complex life cycle and must infect another cell in order to reproduce and thus is classified as an obligate intracellular pathogen. This atypical bacterium commonly causes pharyngitis, bronchitis and atypical pneumonia mainly in elderly and debilitated patients but in healthy adults also. C. pneumoniae infection has been implicated in several chronic lung diseases by serology and direct antigen detection. Acute lower respiratory tract infection caused by C. pneumoniae seems often to precede attacks of asthma in both children and adults but is also involved in some exacerbations of chronic bronchitis. More importantly it seems to be strongly associated with chronic obstructive lung disease irrespective of exacerbation status. Moreover, persistently elevated C. pneumoniae antibody titers have been observed in sarcoidosis and lung cancer (Wiki: Chlamydophila pneumoniae). Baboon Papio cynocephalus 9556 Bank vole Clethrionomys glareolus 447135 Bear Ursus americanus 9643 Birds Passeroidea 175121 Brown Trout Salmo trutta 8032 Buffalo Bison bison 9901 Carnivores Vulpes 9625 Cat Felis catus 9685 Catfishes Siluriformes 7995 Cattle Bos taurus 9913 Chicken Gallus gallus 9031 Chimpanzee Pan troglodytes 9598 chinchillas Chinchillidae 10150 Copper Pheasant Syrmaticus soemmerringii 9067 Deer Cervus elaphus 9860 Deer mouse Peromyscus maniculatus 10042 Dog Canis familiaris 9615 Ducks Anas 8835 Ferret Mustela putorius furo 9669 Fish Hyperotreti 117565 Gerbil Gerbillina 10045 Goat Capra hircus 9925 Gray wolf Canis lupus 9612 Guinea pig Cavia porcellus 10141 Hamster Mesocricetus auratus 10036 Horse Equus caballus 9796 Human Homo sapiens 9606 Macaque Macaca fascicularis 9541 Mongolian Gerbil Meriones unguiculatus 10047 Monkey Platyrrhini 9479 Mouse Mus musculus 10090 None None Parrot Psittacidae 9224 Pig Sus scrofa 9823 Rabbit Oryctolagus cuniculus 9986 Rainbow trout Oncorhynchus mykiss 8022 Rat Rattus 10114 Raven Corvus corax 56781 sei whale Balaenoptera borealis 9768 Sheep Ovis aries 9940 Squirrel Spermophilus richardsonii 37591 Tree shrew Tupaiidae 9393 Trouts, salmons & chars Salmoninae 504568 Turkey Meleagris gallopavo 9103 Vole Microtus ochrogaster 79684 Water buffalo Bubalus bubalis 391902 C. pneumoniae CopN protein vaccine VO_0011432 Subunit vaccine Research Intranasal Escherichia coli heat-labile toxin (LT) Intranasal C. pneumoniae copN Recombinant protein preparation C. pneumoniae CopN (gene lcrE; position 0324 of C. pneumoniae CWL029), was produced in a Bacillus subtilis protein expression system as a soluble protein. Recombinant CopN protein was dissolved in PBS at a concentration of 1 mg/ml and heated to 100 °C for 10 min after which the visible precipitation of protein was discernible. C. pneumoniae preparation was boiled for 10 min in a water bath at a concentration of 2.5 × 10^7 IFU/ml in SPG. E. coli heat-labile toxin, LT (kindly provided by Prof. G. Dougan, Imperial Collage, London, UK) was added to heat-aggregated protein suspension to a final concentration of 12.5 μg/ml (Tammiruusu et al., 2007). BALB/c Mice were immunized intranasally with 40 μg of heat-aggregated CopN/ 40 μl dose or 106 heat-treated C. pneumoniae inclusion forming unit (IFU) (approximately 1 μg of protein)/40 μl dose. Mice immunized intranasally with disrupted HL cells (Mock) or PBS were used as control. Fourteen days after the first immunization, the mice were boosted once with the same dose of antigen. All immunizations were performed under methoxyflurane anaesthesia (Metofane, Pitman-Moore, Mundelein, IL, USA) (Tammiruusu et al., 2007). Intranasal immunization of BALB/c mice with heat-aggregated CopN protein and an Escherichia coli heat-labile toxin (LT) induced a strong immune response. The immunization induced statistically significant protection against intranasal C. pneumoniae challenge, the level of which correlated with the magnitude of CopN-specific lymphocyte proliferation (Tammiruusu et al., 2007). At 14 days after the second immunization, the mice were challenged intranasally with 10^5 IFU of C. pneumoniae in 40 μl of SPG under Metofane anaesthesia. At certain time points after infection, three to six mice were sacrificed, lungs were mechanically homogenized in SPG and dilutions of lung supernatant were cultured on HL cell monolayers (Tammiruusu et al., 2007). The results of this study showed that intranasal immunization of BALB/c mice with heat-aggregated CopN protein and an Escherichia coli heat-labile toxin (LT) induced a strong immune response, detected as IFN-gamma production. The response was significant as compared to PBS-vaccinated mice in the lungs, spleen, and mediastinal lymph nodes 14 days after challenge (Tammiruusu et al., 2007). C. pneumoniae DNA vaccine encoding FabD VO_0011434 DNA vaccine Research pCMVi-UB or linear expression elements [Ref1063:Li et al., 2006] Intramuscular injection (i.m.) Intramuscular injection (i.m.) C. pneumoniae fabD DNA vaccine construction The genome sequence of C. pneumoniae isolate CDC/CWL-029 (ATCC strain VR-1310) was extracted from Genbank (AE001363, 1,230,230 bp). The 1052 annotated genes of C. pneumoniae were imported into a gene-splitting and primer prediction program; primer pairs to amplify 1263 ORFs of 1.5 kb or less were exported. A 1.5 kb maximum ORF length was chosen to ensure sufficient PCR quality and yields, and this generated a few additional fragments (Li et al., 2006). A/J For intranasal inoculation, mice received a light isoflurane inhalation anesthesia. Vaccine protection control mice were inoculated with a low dose of 5 × 10^6 C. pneumoniae elementary bodies in 30 μl SPG buffer (Li et al., 2006). M-ID vaccination with fabD generated a response that resulted in moderately, but significantly reduced total C. pneumoniae lung loads as compared to control mice vaccinated with a plasmid expressing a non-Chlamydia ORF (p ≤ 0.019). This resulted in the ability of fabD to mediate a moderate, but statistically significant level of protection in an inbred A/J mouse respiratory challenge model (Li et al., 2006). High-dose challenge infection was performed 4 weeks after the last gene gun genetic vaccination or low dose inoculation of live C. pneumoniae, and 6 weeks after the last intramuscular-intradermal genetic vaccination, by intranasal inoculation of 1 × 10^8 C. pneumoniae elementary bodies in 30 μl SPG buffer. Mice were sacrificed by CO2 inhalation 2 h, 3 days, 10 days, or 15 days after inoculation, and lungs and spleen were weighed, snap frozen in liquid nitrogen, and stored at −80 °C until further processing (Li et al., 2006). C. pneumoniae DNA vaccine encoding PknD VO_0011424 DNA vaccine Research pCMVi-UB or linear expression elements [Ref1063:Li et al., 2006] Intramuscular injection (i.m.) Intramuscular injection (i.m.) C. pneumoniae serine/threonine-protein kinase, PknD DNA vaccine construction The genome sequence of C. pneumoniae isolate CDC/CWL-029 (ATCC strain VR-1310) was extracted from Genbank (AE001363, 1,230,230 bp). The 1052 annotated genes of C. pneumoniae were imported into a gene-splitting and primer prediction program; primer pairs to amplify 1263 ORFs of 1.5 kb or less were exported. A 1.5 kb maximum ORF length was chosen to ensure sufficient PCR quality and yields, and this generated a few additional fragments (Li et al., 2006). A/J For intranasal inoculation, mice received a light isoflurane inhalation anesthesia. Vaccine protection control mice were inoculated with a low dose of 5 × 10^6 C. pneumoniae elementary bodies in 30 μl SPG buffer (Li et al., 2006). IM-ID vaccination with CPn0095 (pknD) generated a response that resulted in moderately, but significantly reduced total C. pneumoniae lung loads as compared to control mice vaccinated with a plasmid expressing a non-Chlamydia ORF (p ≤ 0.019). This resulted in the ability of CPN0095 to mediate a moderate, but statistically significant level of protection in an inbred A/J mouse respiratory challenge model (Li et al., 2006). High-dose challenge infection was performed 4 weeks after the last gene gun genetic vaccination or low dose inoculation of live C. pneumoniae, and 6 weeks after the last intramuscular-intradermal genetic vaccination, by intranasal inoculation of 1 × 10^8 C. pneumoniae elementary bodies in 30 μl SPG buffer. Mice were sacrificed by CO2 inhalation 2 h, 3 days, 10 days, or 15 days after inoculation, and lungs and spleen were weighed, snap frozen in liquid nitrogen, and stored at −80 °C until further processing (Li et al., 2006). C. pneumoniae DNA vaccine encoding Ssb VO_0011425 DNA vaccine Research pCMVi-UB or linear expression elements [Ref1063:Li et al., 2006] Intramuscular injection (i.m.) Intramuscular injection (i.m.) C. pneumoniae single-stranded DNA-binding protein, ssb DNA vaccine construction The genome sequence of C. pneumoniae isolate CDC/CWL-029 (ATCC strain VR-1310) was extracted from Genbank (AE001363, 1,230,230 bp). The 1052 annotated genes of C. pneumoniae were imported into a gene-splitting and primer prediction program; primer pairs to amplify 1263 ORFs of 1.5 kb or less were exported. A 1.5 kb maximum ORF length was chosen to ensure sufficient PCR quality and yields, and this generated a few additional fragments (Li et al., 2006). A/J For intranasal inoculation, mice received a light isoflurane inhalation anesthesia. Vaccine protection control mice were inoculated with a low dose of 5 × 10^6 C. pneumoniae elementary bodies in 30 μl SPG buffer (Li et al., 2006). Mice vaccinated with candidate gene ssb showed significant reduction of spleen chlamydial loads as compared to naïve, non-protected control mice (p ≤ 0.048). This resulted in the ability of ssb to mediate a modest, but significant level of protection in an inbred A/J mouse respiratory challenge model (Li et al., 2006). High-dose challenge infection was performed 4 weeks after the last gene gun genetic vaccination or low dose inoculation of live C. pneumoniae, and 6 weeks after the last intramuscular-intradermal genetic vaccination, by intranasal inoculation of 1 × 10^8 C. pneumoniae elementary bodies in 30 μl SPG buffer. Mice were sacrificed by CO2 inhalation 2 h, 3 days, 10 days, or 15 days after inoculation, and lungs and spleen were weighed, snap frozen in liquid nitrogen, and stored at −80 °C until further processing (Li et al., 2006). C. pneumoniae DNA vaccine pHSP-60 VO_0004555 DNA vaccine Research pCI [Ref2676:Svanholm et al., 2000] intranasal immunization IL-12 (Svanholm et al., 2000) intranasal immunization DNA vaccine construction VO_0003057 Immunization with this vaccine resulted in signi®cant protection, as measured by a lower bacterial load and a less severe pathological outcome after infection with C. pneumoniae (Svanholm et al., 2000). C. pneumoniae LcrE protein vaccine VO_0011435 Subunit vaccine Research Subcutaneous injection Either Freund's or Alum adjuvants Subcutaneous injection C. pneumoniae LcrE Recombinant protein preparation A 1218-kb DNA fragment containing the lcrE gene (GenBank ID 15618244, Locus tag CPn0324) was amplified by PCR, using C. pneumoniae (CWL029 ATCC) DNA as template. The PCR was performed in a GeneAmp II (Applied Biosystems, Foster City, CA, USA) thermocycler with Advantage GC cDNA polymerase (Clontech, Mountain View, CA, USA), and the amplification conditions were set as recommended by the manufacturer. The amplicon was digested with NdeI and BamHI and inserted into p6HisF-11d (icl) pET vector by digesting it with the same enzymes and replacing the icl gene (Faludi et al., 2009). BALB/c The mice in groups of 25 were immunized subcutaneously into the tail base with the purified LcrE protein diluted in phosphate buffered saline (PBS) at a dose of 20 μg mixed with 25 μl Alum (Aluminum hydroxide Gel, Sigma) or 75 μl Freund's adjuvants (Chemicon International, Temecula, CA, USA; 1st inoculation with complete and 2nd and 3rd inoculations with incomplete Freund's adjuvant) in 0.15-ml volume 3 times at 3-week intervals (Faludi et al., 2009). The immunogenicity and protective effect of recombinant LcrE protein combined either with Freund's or Alum adjuvant were investigated in mice. The immunization with both protocols resulted in a significant reduction of the number of viable C. pneumoniae in the lungs after challenge. Results confirm that LcrE induces protective immunity in mice (Faludi et al., 2009). Two weeks after the last immunization, the immunized and non-immunized mice (absolute naive animals) were challenged with 4×10^5 inclusion forming unit (IFU) C. pneumoniae (CWL029, ATCC) in 25 μl PBS intranasally under pentobarbital sodium anesthesia (Faludi et al., 2009). The presence of LcrE-specific IFN-gamma-producing cells in LcrE+Alum-immunized mice indicates Th1 type response. IFN-gamma responses were measured in spleen cells collected 2 weeks after last immunization and were significantly higher than mock-immunized mice (Faludi et al., 2009). LcrE-specific IgA level was higher in both the sera and the lungs after using Freund's adjuvant than non-immunized mice at the time of the challenge (Faludi et al., 2009). licensed Chlamydia pneumonia human vaccine Generic Unknown VO_0012173 Inactivated or "killed" vaccine Licensed A generic representation of vaccines developed to prevent pneumonia caused by Chlamydia pneumoniae in humans, utilizing inactivated bacterial preparations to elicit protective immune responses. These vaccines are designed to provide immunity without the risk of causing disease. copN Chlamydophila pneumoniae VO_0010884 33241669 CDD:274206 182082 ? CopN 4.72 42139.89 458 type strain >NP_876610.1 CopN [Chlamydophila pneumoniae TW-183] MAASGGTGGLGGTQGVNLAAVEAAAAKADAAEVVASQEGSEMNMIQQSQDLTNPAAATRTKKKEEKFQTL ESRKKGEAGKAEKKSESTEEKPDTDLADKYASGNSEISGQELRGLRDAIGDDASPEDILALVQEKIKDPA LQSTALDYLVQTTPPSQGKLKEALIQARNTHTEQFGRTAIGAKNILFASQEYADQLNVSPSGLRSLYLEV TGDTHTCDQLLSMLQDRYTYQDMAIVSSFLMKGMATELKRQGPYVPSAQLQVLMTETRNLQAVLTSYDYF ESRVPILLDSLKAEGIQTPSDLNFVKVAESYHKIINDKFPTASKVEREVRNLIGDDVDSVTGVLNLFFSA LRQTSSRLFSSADKRQQLGAMIANALDAVNINNEDYPKASDFPKPYPWS Protective antigen Results of this study showed that intranasal immunization of BALB/c mice with heat-aggregated CopN protein and an Escherichia coli heat-labile toxin (LT) induced a strong immune response. The immunization induced statistically significant protection against intranasal C. pneumoniae challenge, the level of which correlated with the magnitude of CopN-specific lymphocyte proliferation [Ref1060:Tammiruusu et al., 2007]. FabD Chlamydophila pneumoniae CWL029 VO_0010895 894994 15618217 CPn0297 AE001363 NP_224502 115713 334770 335696 - malonyl CoA-acyl carrier protein transacylase 4.92 31463.85 308 >NC_000922.1:334770-335696 Chlamydophila pneumoniae CWL029 chromosome, complete genome ATCATACCTCTGATAGGAATTTTTCAATCTGAGCAAAAGTACCAAGACTTGTAATCGGTTTAGAAATCCC TATAGAGCGATTTAAACCAGCCAAAACTTTTCCTGGACCTAATTCTAAAAACTCATCCACCTCTGATTCG ATATGGTAACAACTCTGATACCATAACGTAGGTGATGTCATTTGCCGAGCTAAACACTCTCGCATTTCTT CAGTATTTACTAAAGATTTTCCTACCACGTGTGACACTAAGGGAAGGCTAGAATCTTTCATGCATAAAGC ATAAATGTCTGGAGCTAAGCCATCTTGAGCAACTTGCATTAAAGGAGTATGAAATGCTCCAGACACCTTT AAACGAACTGCTTTTTTACATCCTAAATCACGAAATAACTCAATCGCTTGGTCTACTTTTTCTGCTATTC CAGCCACTACAAGCTGTTTGGGTGCATTATAATTAGCAATCCAAATTCCTTGACCAAGACTTGTTATATT TTCCTCTATAACTTCAGAGGGAAGCCCTAATAAAGCCGCCATAGCCCCTGGGCTCTGATTACAAGCTTCA TTCATTAACTGACCACGCTTTCTAACAAGCTCAAGGCCGTCGAGCACGGAGATTCTATCGGAAGCAACTA AAGCAGTATACTCCCCTAAACTTAATCCAGAGACTAAAGAAGGCTGAATAGAAGAACGCTGAGATAGAAC CTTTACCACAGCCATGCTATGAAGATAAATAGCTAGCTGACTATGTACTGTTTCCATCAAAAGATCCTCA GGACCTTCAAACATAATTGAAGTCAGAGAAAATCCTAACCTTTCATTAGCAAAATCAAAAAGCTCTCTAA CCTCAGGATACTCCATATATAGGTCTTGTCCCATACCTACATATTGGCTCCCTTGTCCTGGGAACAAAAA AGCATAACGTTTTTTCA >NP_224502.1 malonyl CoA-acyl carrier protein transacylase [Chlamydia pneumoniae CWL029] MKKRYAFLFPGQGSQYVGMGQDLYMEYPEVRELFDFANERLGFSLTSIMFEGPEDLLMETVHSQLAIYLH SMAVVKVLSQRSSIQPSLVSGLSLGEYTALVASDRISVLDGLELVRKRGQLMNEACNQSPGAMAALLGLP SEVIEENITSLGQGIWIANYNAPKQLVVAGIAEKVDQAIELFRDLGCKKAVRLKVSGAFHTPLMQVAQDG LAPDIYALCMKDSSLPLVSHVVGKSLVNTEEMRECLARQMTSPTLWYQSCYHIESEVDEFLELGPGKVLA GLNRSIGISKPITSLGTFAQIEKFLSEV Protective antigen M-ID vaccination with fabD generated a response that resulted in moderately, but significantly reduced total C. pneumoniae lung loads as compared to control mice vaccinated with a plasmid expressing a non-Chlamydia ORF (p ≤ 0.019). This resulted in the ability of fabD to mediate a moderate, but statistically significant level of protection in an inbred A/J mouse respiratory challenge model [Ref1063:Li et al., 2006]. GroEL Chlamydophila pneumoniae WP_010883533 CDD:223535 CDD:295468 83558 ? chaperonin GroEL 5.03 54952.93 584 Chaperonin GroEL (HSP60 family) [Posttranslational modification, protein turnover, chaperones]; COG0459 >WP_010883533.1 chaperonin GroEL [Chlamydia pneumoniae] MSEQEKLSNYNADKKLFSGIDKLFQIVKGSYGPKQSLSPTSFFKERGFYAISQTELSNSYENLGVDFAKA MVNKIHKEHSDGATTGLILLHAILQESYAALEKGISTHKLIASLKLQGEKLQEALQQQSWPIKDALKVRN IIFSSLHMPTIADHFYNAFSVVGPEGLISITKERENDKTSMDVFQGFKIPAGYASTYFVSDTASRLTRIA HPLILITDRKISMIHSLLPLLQEISEQNQHLIIFCEDIDPDVLATLVVNKLQGLLQVTVVTIPQLSTTNQ ELAEDIALFTGTHICPCQEASHVLAPEMVTLGSCLSIEISESQTTLIGGLHIPEVLTLKTRQLAEEIRTT SCLETKKRLIKSTNRLQSSVAILPTDEDNEPLYTLALKIMESALSRGYVPGGGVALFYASLTLGTPKDDA DENSIAISLLQKACCAPLKLLATNADLDGDAVIAKLSSLGTTSLGISVFSREIEDLIAGGILDSLATTST ILAQALDTAILVLSSKILILENQYEISTL Protective antigen Immunization of mice with a single construct containing multiple epitopes derived from ApoB100, hHSP60 and Cpn was more effective in reducing early atherosclerotic lesions.[Ref4689:Lu et al., 2012] Immunization with pmomp or phsp60 showed 1.2–1.5 log reduction in the mean lung bacterial counts after the challenge.[Ref1056:Penttilä et al., 2000] Ifng (Interferon gamma) Mouse 15978 33468859 NM_008337 NP_032363.1 MGI:107656; UniProt:P01580 10090 ? >gi|145966741|ref|NM_008337.3| Mus musculus interferon gamma (Ifng), mRNA ATAGCTGCCATCGGCTGACCTAGAGAAGACACATCAGCTGATCCTTTGGACCCTCTGACTTGAGACAGAA GTTCTGGGCTTCTCCTCCTGCGGCCTAGCTCTGAGACAATGAACGCTACACACTGCATCTTGGCTTTGCA GCTCTTCCTCATGGCTGTTTCTGGCTGTTACTGCCACGGCACAGTCATTGAAAGCCTAGAAAGTCTGAAT AACTATTTTAACTCAAGTGGCATAGATGTGGAAGAAAAGAGTCTCTTCTTGGATATCTGGAGGAACTGGC AAAAGGATGGTGACATGAAAATCCTGCAGAGCCAGATTATCTCTTTCTACCTCAGACTCTTTGAAGTCTT GAAAGACAATCAGGCCATCAGCAACAACATAAGCGTCATTGAATCACACCTGATTACTACCTTCTTCAGC AACAGCAAGGCGAAAAAGGATGCATTCATGAGTATTGCCAAGTTTGAGGTCAACAACCCACAGGTCCAGC GCCAAGCATTCAATGAGCTCATCCGAGTGGTCCACCAGCTGTTGCCGGAATCCAGCCTCAGGAAGCGGAA AAGGAGTCGCTGCTGATTCGGGGTGGGGAAGAGATTGTCCCAATAAGAATAATTCTGCCAGCACTATTTG AATTTTTAAATCTAAACCTATTTATTAATATTTAAAACTATTTATATGGAGAATCTATTTTAGATGCATC AACCAAAGAAGTATTTATAGTAACAACTTATATGTGATAAGAGTGAATTCCTATTAATATATGTGTTATT TATAATTTCTGTCTCCTCAACTATTTCTCTTTGACCAATTAATTATTCTTTCTGACTAATTAGCCAAGAC TGTGATTGCGGGGTTGTATCTGGGGGTGGGGGACAGCCAAGCGGCTGACTGAACTCAGATTGTAGCTTGT ACCTTTACTTCACTGACCAATAAGAAACATTCAGAGCTGCAGTGACCCCGGGAGGTGCTGCTGATGGGAG GAGATGTCTACACTCCGGGCCAGCGCTTTAACAGCAGGCCAGACAGCACTCGAATGTGTCAGGTAGTAAC AGGCTGTCCCTGAAAGAAAGCAGTGTCTCAAGAGACTTGACACCTGGTGCTTCCCTATACAGCTGAAAAC TGTGACTACACCCGAATGACAAATAACTCGCTCATTTATAGTTTATCACTGTCTAATTGCATATGAATAA AGTATACCTTTGCAACC >gi|33468859|ref|NP_032363.1| interferon gamma [Mus musculus] MNATHCILALQLFLMAVSGCYCHGTVIESLESLNNYFNSSGIDVEEKSLFLDIWRNWQKDGDMKILQSQI ISFYLRLFEVLKDNQAISNNISVIESHLITTFFSNSKAKKDAFMSIAKFEVNNPQVQRQAFNELIRVVHQ LLPESSLRKRKRSRC IFN-gamma plays a critical role in Th1 type immune response. It is important for protection against infections by various viruses and intracellular bacteria. Vaximmutor The experimental data demonstrated that three time vaccinations with BCG in BALB/c mice induced strong TB Ag-specific IFN-gamma immune responses in splenocytes [Ref2101:Wang et al., 2009]. IgA Mus musculus 238447 AC160982 10090 12 8607 12639 - immunoglobulin heavy constant alpha Also known as IgA; Igh-2 >gi|121699722:8607-12639 Mus musculus immunoglobulin heavy chain complex (Igh) on chromosome 12 AGTACTGGGGGACCTCTTTGCTGCCAAACGGGCCTCGAACAGTTGTAACAGTGAGTGCTGTGCTGTAGAA CAAGCTCAGTAGGAAGAGGGTGAGGAAGGTCACAGTGGTGGGCCACAGGCTGGCACCTGGGGCCTCTTCC TCCAGGATGTCTTCTGACTGGTCCAGTAGCACATAGGAAAGTGGCTCTTGACGTTCTGTAAGACATAGAT GACCTTCTAGATCCAAACCCATGGGGATGGGGGCTCAGACTTAAGGTTTCTGCTTCTATGCCTCCTTGGG CTTTGGGGACAGTGGTGGTAGGGGTCCCTTATTCCCGGGAAGGGACTTGTTCAGGGATAATGAGGAGGCA GGGTCCCAGGTAAGGGACTGGAATCCCAGCAGTTCTTGAGATGGCCCCAAGACCCATCTCTCTCTCTTAG GGAAACCTTAATTAGAGACCTGTCATGGTAAGAGAGTTGTTTCTGTCAAACTCTGAGAAGAGTTTGAACC CAAGGCTCCTTAGGTCTCAGTCCTTTCTAGATATTTAGCAATACCTCCCTAAACCCCAGTTCTTAGGCTA ATCTTGGCTTGGGTACTAGGGTTGTGTAAGATCAGACACCTTCAAACAGATACAGGCCAATGTGATTTCT GGGCCAAAGTTAGACTACCAAGGCCTGGACATGTGGTCAGAGGACTCTGTTGCATTCTTAAGAGCTGTGA CTGGGGGTTAAGCAACAGTAAAGACCCCCAGTAGAGCCAACCCTGCTGTCCTCAGGTTCTCTGCGCACAG AGTTTCATTTTAAGTGGCAGTAGGAAATGTGTACTGATAGTCAACCACTCGTATTTCTGTCACTGCAGCC ATCCATCAATCCATCCATCATCCCCATCGTTCATCCTTGTAGCCAGCCATCCATTACCCTCCAGCCGCTC ACTCATCATCTTTCCCGACTATCGTGATTCTCCAGCTTCTCTGCCCCCTCTCCCTGTGGGGATTCAGTCT TTCACCTATTGACTCCTCCTTACTAGGATTCTCTGTCATGGGCCAGGCCTTGGATTCCATGGGTGGCTAT GGTACTTTTCTGAGTCAGGTTTCCCAAGCTGGTCTGTTGCTCTTGCTATTCTCAGGGAACTGGACTTTCA AGCTGGAGAGTATCCAGGGCATGCATGGGCCTTTACTCCACTCTTGCTCTGAGAGCAGAGGGAAGTTGCT AGAAACCAGCAACTCCTCCCCCCCCCCCCCGAAGTTCTGAAGGCCTGTGAGACAGGAGCAGGGCCCCCAC TGCCCTCTTGTGGACACCTGGGCTCCAAGTATACCTGGTTGTAGAACTTTGTGTTCTAGGGGTGCCCATG GAGGAGGCCGAGGCCTGTGTGGGAGTGGTCTCCATGGCCTGCTCCTGCTTCTTCCCAGATTTGCCTCTTA TCCTGCTTCTGGTTTGTGATACTTGGGCTCAGGATGGGAAGGGAGACTTAGGTTAGAAAGGGGGCACCTG GAGGGGCCTATGCCCTTGTCCATTGTGTGTAGTTGTCAGTGTCGGGCCTGGAAATTCTCCCGGGGGCTTG GAGGGGACTCCCCTTGCTTTCCAGAAGCTGGGTGTGGGCTGTGAACTTCATCTTCCTCCAGGGTTCAGGT CTGTGTGAGTGTGCAAATGTGAGTGTCTGTGCATGTATGCCCATGTGCATGTATGCAGAACAGGGTGTAT GCCCATGTGCATGTGTGAAGAGCAGGGTGCTGCTGAGGGTTGTCTGTGCCATGCTATATGTCTTTCTCAT GAGTCAGTGGTCACCCTGAATGCATGTTTCCATTCAGGGATGGCCTACTGAGGGTGCGTGGCATCTTCTT CCCAGTGCCCCTGTGTTCATCCCTTCATTCTCATACCATCATCTCTATTGTGACCCCCACACGGCACCAG CCTTGATGGTGCTACCCTTTTGCTCCATCTATCCCTGTCTTGTTTGGGTTAGAAGCTGCGGTCTAATAAA CAGCCACACCACCCACCACTCAGAGTACTTGTGCAGCAACCCACTGCCCTGGGGACTCTCCCATGAGCTT TGCCTTCTTGGCTGAGTCTGCTCGCCTTGGATTTCATCCCCAGTTTATTCTTACTTCCCATTCACTCATT GCACATTCACAGGGCAGGTGCACACACTCTCATGTTTCCACCAACATGAACACACATAGATATATGCATG CTCATAGGTATGCACAGGCACACACTTGCTCACAGGGACATAGATATAGTGTGTCCACATATGTACTTAT ACCCATATACATACCTATAAACCATAGGTGCACACAAACTCACTCCTCTCTTGCTGCACACAGGTACACA CATGAAGGCACATGGACCCATCCATAAGCACTCACCAATACATAGACATGCATACACATATACTCTAGGC ATGAAGGGTCTTCAAAGTCTCCGAGGCCTTACAAGCTTAGGTGGTGGTGTTTCTCCCTCCCTGGGCCCTG ACCCCTCCCTGTGTTCTGTAGACCCTAAGGATGATGGACAGGCACTGGATGGAAGTGCAGGGATACTTTG GATGAGCACAGAGTTTATTTCAGGAGTAGGGACAGGCAGGGTGGCTCAGTAGCAGATGCCATCTCCCTCT GACATGATCACAGACACGCTGACATTGGTGGGTTTACCCGACAGACGGTCGATGGTCTTCTGGGTGAAGT TCATGGGCAAGGCCTCGTGGCCCACCATGCAGGAGTACTGGTCACCCTGTTTCCAGAGTTCAGCTGATAC ACGCAACACGCTTGTCACCAGGTAGGTGGTGGCTCCCTCGCCTGGCTCCTTTAGGGGCTCAAACACTAGG TAGCTTTCTGGGGACAGCTCCTCATTTCCATGCAGCCATCGCACCAGCACTTCTTTAGGGTTGAAAGCTC GCACCAGGCATGTCAGGGACACGAGCTCATTCAGGGCCAGCTCCTCCGACGGCGGCGGTAGCAGGTGGAC CTGGGGTGGGAAGGTGTTCACTGGAAGGTAGAAAGAAGAGTTATGGCTCAGACAAGGAGAGCAAGACCCC TCTGCCCTTCCCTTCTGGGCAGTTCCTCAGATAGCTCCAATTTCCCTCTGTGATATAAGGACAGGAGCAG TTAGTTGAGCATCTGTATTATAGGAAGAAAGCAGGCATGTGAGCAGGGAACGTCATACAATGTCCCGGGT ATGCATCTGGGCTCACCTGTGATTTTGGCAATTGTGCCAGTTAAGGTGTCAGACTCAGGATGGGTAACTG TGCACTTGAATGATGCGCCACTGTTCCAGCGCTCAGCACAGCCAGGCAGGACGCTGGACACACTGTAGCA GCCGCAGGAATTCTGCACAGCTTTCTTCTGCACTGCATCCTTCCCAGTGGAGGGCTCCCAGGTGAAGACA GCTCCCTCAGGATTTCTCAGGCCATTCAGAGTACATGTGAGGCTGGCATCTGAACCCAGGAGCAGGTCCT CAAGAGCTGGCCGCTGCAGTGACAGGCTGGGATGGCAGGAAGGAGGACAAGGAGGACAAGGAGGAGGAGG ACCTGTAACAGAGAAGTCCTAGCAAATCAGTATATTCTCCTTTTCTCCTTTGCTGTCCCCTTTTCTGGAT GTTCTGAGGCCTCAGTTCCTTATGGCCTGTTTACGCTTCCCTTCCCCCACCCCCATGGGAGGTTTCTGAG GGTCCCTGTGAGGGTGTGCCTCAGAGGGATATATGGATCTAGATAAGGTAGAACTTATCCCACCCCCAGC TGACCCCCTAACGTTCTTTACCAGAGCACTTCACATCCAATTCTTGGACGGCGTTAGAGTCATGTTGCAC GGAACATTTCACGGATTCTCCTTCTGGGCACTCGACAGCTGGCAGGGTCAACTGGCTGCTCATGGTGTAC CCTCCCCCAGAGGCCAGGGCAGGTGGGAAGTTTACGGTGGTTATATCCTTCCCACTCTTTCCCCAGGTCA CATTCATCGTGCCGGAAGGGAAGTAATCGTGAATCAGGCAGCCGATTATCACTGGGTCACTTGACAGAGC TCGTGGGAGTGTCAGTGGGTAGATGGTGGGATTTCTCGCAGAC Vaximmutor LcrE Chlamydophila pneumoniae CWL029 VO_0010883 895078 15618244 CPn0324 AE001363 NP_224529 115713 369491 370690 + low calcium response protein E 4.72 41321.12 399 >NC_000922.1:369491-370690 Chlamydophila pneumoniae CWL029 chromosome, complete genome TATGGCAGCATCAGGAGGCACAGGTGGTTTAGGAGGCACTCAGGGTGTCAACCTTGCAGCTGTAGAAGCT GCAGCTGCAAAAGCAGATGCAGCAGAAGTTGTAGCCAGCCAAGAAGGTTCTGAGATGAACATGATTCAAC AATCTCAGGACCTGACAAATCCCGCAGCAGCAACACGCACGAAAAAAAAGGAAGAGAAGTTTCAAACTCT AGAATCTCGGAAAAAAGGAGAAGCTGGAAAGGCTGAGAAAAAATCTGAATCTACAGAAGAGAAGCCTGAC ACAGATCTTGCTGATAAGTATGCTTCTGGGAATTCTGAAATCTCTGGTCAAGAACTTCGCGGCCTGCGTG ATGCAATAGGAGACGATGCTTCTCCAGAAGACATTCTTGCTCTTGTACAAGAGAAAATTAAAGACCCAGC TCTGCAATCCACAGCTTTGGACTACCTGGTTCAAACGACTCCACCCTCCCAAGGTAAATTAAAAGAAGCG CTTATCCAAGCAAGGAATACTCATACGGAGCAATTCGGACGAACTGCTATTGGTGCGAAAAACATCTTAT TTGCCTCTCAAGAATATGCAGACCAACTGAATGTTTCTCCTTCAGGGCTTCGCTCTTTGTACTTAGAAGT GACTGGAGACACACATACCTGTGATCAGCTACTTTCTATGCTTCAAGACCGCTATACCTACCAAGATATG GCTATTGTCAGCTCCTTTCTAATGAAAGGAATGGCAACAGAATTAAAAAGGCAGGGTCCCTACGTACCCA GTGCGCAACTACAAGTTCTCATGACAGAAACTCGTAACCTGCAAGCAGTTCTTACCTCGTACGATTACTT TGAAAGTCGCGTTCCTATTTTACTCGATAGCTTAAAAGCTGAGGGAATCCAAACTCCTTCTGATCTAAAC TTTGTGAAGGTAGCTGAGTCCTACCATAAAATCATTAACGATAAGTTCCCAACAGCATCTAAAGTAGAAC GAGAAGTCCGCAATCTCATAGGAGACGATGTTGATTCTGTGACCGGTGTCTTGAACTTATTCTTTTCTGC TTTACGTCAAACGTCGTCACGCCTTTTCTCTTCAGCAGACAAACGTCAGCAATTAGGAGCTATGATTGCT AATGCTTTAGATGCTGTAAATATAAACAATGAAGATTATCCCAAAGCATCAGACTTCCCTAAACCCTATC CTTGGTCATG >NP_224529.1 low calcium response protein E [Chlamydia pneumoniae CWL029] MAASGGTGGLGGTQGVNLAAVEAAAAKADAAEVVASQEGSEMNMIQQSQDLTNPAAATRTKKKEEKFQTL ESRKKGEAGKAEKKSESTEEKPDTDLADKYASGNSEISGQELRGLRDAIGDDASPEDILALVQEKIKDPA LQSTALDYLVQTTPPSQGKLKEALIQARNTHTEQFGRTAIGAKNILFASQEYADQLNVSPSGLRSLYLEV TGDTHTCDQLLSMLQDRYTYQDMAIVSSFLMKGMATELKRQGPYVPSAQLQVLMTETRNLQAVLTSYDYF ESRVPILLDSLKAEGIQTPSDLNFVKVAESYHKIINDKFPTASKVEREVRNLIGDDVDSVTGVLNLFFSA LRQTSSRLFSSADKRQQLGAMIANALDAVNINNEDYPKASDFPKPYPWS Protective antigen The immunogenicity and protective effect of recombinant LcrE protein combined either with Freund's or Alum adjuvant were investigated in mice. The immunization with both protocols resulted in a significant reduction of the number of viable C. pneumoniae in the lungs after challenge. Results confirm that LcrE induces protective immunity in mice [Ref1059:Faludi et al., 2009]. DNA immunization given as a priming and followed by a protein booster significantly reduced the number of viable bacteria in the lungs after challenge with C. pneumoniae. These results confirm that immunization with pΔRCLcrE can be an effective part of a vaccination schedule against C. pneumoniae. [Ref4779:Faludi and Szab�, 2011] PknD Chlamydophila pneumoniae CWL029 VO_0010894 895704 161353778 CPn0095 AE001363 NP_224303 115713 115994 118792 + serine/threonine protein kinase 6.03 102446.37 932 PknD; responsible for phosphorylation of proteins on serine and threonine residues; similar to eukaryotic Ser/Thr kinases; in Chlamydia trachomatis itseems to interact with Pkn1, another serine/threonine-protein kinase >NC_000922.1:115994-118792 Chlamydophila pneumoniae CWL029 chromosome, complete genome TTTGGAGCGCTATGATATTGTTAGAATTATTGGAAAGGGAGGCATGGGTGAAGTCTATCTTGCCTACGAT CCTGTATGTTCTCGTAAAGTAGCTCTTAAAAAAATTCGTGAAGATCTTGCAGAAAATCCTCTTTTGAAAA GGAGGTTTTTACGAGAGGCAAGAATTGCCGCTGACCTTATTCATCCTGGTGTTGTTCCTGTCTATACTAT TTACAGCGAGAAAGATCCTGTATACTACACGATGCCCTACATAGAGGGATATACACTAAAAACCTTACTG AAGAGTGTATGGCAAAAGGAATCCCTGTCTAAGGAATTAGCAGAGAAAACTTCTGTAGGGGCATTTCTTT CTATCTTTCATAAGATCTGCTGCACTATAGAATATGTCCATTCTCGGGGCATTCTTCATCGCGACCTTAA ACCCGATAACATCTTATTAGGTCTTTTTAGTGAGGCTGTAATCTTAGATTGGGGAGCAGCAGTTGCCTGT GGAGAAGAAGAGGATCTTCTTGATATAGATGTCAGCAAAGAGGAGGTGCTCTCTTCAAGAATGACAATTC CAGGAAGAATAGTAGGGACTCCAGATTATATGGCTCCTGAGAGGCTCCTGGGCCATCCAGCTTCTAAAAG TACAGACATTTATGCTTTAGGAGTGGTTCTTTATCAGATGCTCACTCTCTCTTTTCCTTATAGAAGAAAA AAAGGAAAGAAAATAGTTCTTGACGGTCAGAGAATTCCAAGTCCTCAAGAGGTAGCTCCTTATCGAGAAA TCCCTCCGTTTCTTTCCGCTGTAGTGATGAGAATGTTGGCTGTAGATCCTCAAGAGCGCTATTCTTCGGT AACAGAGCTTAAGGAAGATATCGAGAGTCATCTGAAAGGGAGTCCTAAATGGACTTTAACCACAGCCCTG CCACCTAAAAAATCTTCTAGTTGGAAGCTAAACGAACCTATTTTACTTTCTAAGTATTTTCCAATGTTGG AGGTCTCTCCAGCGTCATGGTACAGTTTAGCAATCTCTAATATTGAGAGTTTTTCTGAGATGCGCTTGGA GTATACTCTTTCTAAAAAAGGCTTGAACGAAGGCTTTGGTATTTTACTTCCCACGTCAGAAAATGCTTTA GGGGGAGATTTTTACCAGGGGTATGGCTTTTGGCTGCATATTAAGGAGAGAACCTTATCCGTGTCTCTGG TGAAAAATAGCCTAGAAATCCAGAGGTGCTCTCAAGATTTGGAATCTGATAAAGAGACCTTCTTGATAGC TTTAGAGCAGCATAATCATAGTTTATCTTTGTTTGTCGATGGTACGACTTGGCTTATCCATATGAATTAT CTGCCAAGTCGTAGTGGGCGAGTCGCTATCATAGTTCGCGATATGGAAGATATCCTGGAAGATATAGGCA TTTTTGAAAGTAGTGGCTCTTTGAGGGTCAGTTGTCTTGCTGTTCCTGACGCTTTTCTTGCTGAGAAGTT ATATGATCGCGCTTTAGTGCTTTACCGAAGGATCGCAGAATCTTTCCCAGGACGTAAAGAAGGTTATGAA GCAAGGTTCAGAGCAGGAATTACAGTTTTAGAGAAGGCCTCTACAGATAATAATGAACAGGAATTTGCTC TAGCCATTGAAGAATTCTCAAAATTACATGACGGGGTTGCTGCTCCCTTAGAATACCTTGGTAAGGCTTT AGTATATCAGAGACTCCAAGAGTATAATGAAGAAATTAAGAGTTTGCTATTAGCATTGAAACGTTATTCG CAGCATCCTGAAATCTTTAGGCTTAAAGACCATGTGGTTTACCGACTCCATGAGAGCTTTTATAAACGGG ATCGCCTTGCTCTGGTGTTCATGATTTTAGTATTGGAAATAGCTCCCCAGGCAATCACTCCAGGGCAGGA AGAAAAAATCCTGGTTTGGTTAAAGGACAAATCTCGGGCTACCTTATTTTGCCTCCTGGATCCCACGGTC TTAGAGCTGCGCTCTTCTAAAATGGAATTATTTTTAAGTTATTGGTCTGGGTTTATTCCCCATCTCAATA GTCTATTTCATAGAGCTTGGGATCAAAGCGATGTGCGAGCTTTGATCGAGATTTTCTATGTTGCTTGTGA TCTTCATAAATGGCAGTTTCTCTCTTCTTGTATCGACATATTTAAAGAGTCTCTTGAGGATCAGAAAGCC ACAGAAGAGATTGTTGAGTTCTCTTTCGAGGATTTAGGGGCATTTCTTTTTGCTATTCAGAGCATCTTTA ACAAGGAAGATGCAGAGAAGATCTTTGTTTCTAATGATCAATTATCGCCAATCCTTCTTGTTTATATATT CGATCTTTTTGCAAATCGTGCTCTTCTGGAATCTCAAGGAGAGGCTATTTTTCAGGCTTTGGATCTCATC CGAAGTAAAGTTCCTGAAAATTTTTATCATGATTACTTGCGGAATCATGAAATCCGAGCGCATCTTTGGT GCCGCAATGAGAAGGCTCTAAGCACGATTTTTGAAAACTATACAGAGAAACAGCTAAAGGATGAGCAACA TGAACTGTTCGTTCTCTATGGATGTTACCTTGCTCTTATACAAGGTGCTGAGGCGGCAAAGCAGCATTTT GATGTATGTCGTGAAGATCGCATTTTCCCTGCTTCATTATTAGCTAGAAATTACAATCGTTTAGGTCTTC CCAAAGATGCTCTTAGCTATCAAGAGCGGCGTTTGTTATTGCGACAAAAGTTTCTCTATTTCCATTGTCT TGGTAACCACGACGAGCGTGACTTATGCCAGACTATGTATCACCTCTTAACCGAAGAATTTCAGCTTTA >NP_224303.2 serine/threonine protein kinase [Chlamydia pneumoniae CWL029] MERYDIVRIIGKGGMGEVYLAYDPVCSRKVALKKIREDLAENPLLKRRFLREARIAADLIHPGVVPVYTI YSEKDPVYYTMPYIEGYTLKTLLKSVWQKESLSKELAEKTSVGAFLSIFHKICCTIEYVHSRGILHRDLK PDNILLGLFSEAVILDWGAAVACGEEEDLLDIDVSKEEVLSSRMTIPGRIVGTPDYMAPERLLGHPASKS TDIYALGVVLYQMLTLSFPYRRKKGKKIVLDGQRIPSPQEVAPYREIPPFLSAVVMRMLAVDPQERYSSV TELKEDIESHLKGSPKWTLTTALPPKKSSSWKLNEPILLSKYFPMLEVSPASWYSLAISNIESFSEMRLE YTLSKKGLNEGFGILLPTSENALGGDFYQGYGFWLHIKERTLSVSLVKNSLEIQRCSQDLESDKETFLIA LEQHNHSLSLFVDGTTWLIHMNYLPSRSGRVAIIVRDMEDILEDIGIFESSGSLRVSCLAVPDAFLAEKL YDRALVLYRRIAESFPGRKEGYEARFRAGITVLEKASTDNNEQEFALAIEEFSKLHDGVAAPLEYLGKAL VYQRLQEYNEEIKSLLLALKRYSQHPEIFRLKDHVVYRLHESFYKRDRLALVFMILVLEIAPQAITPGQE EKILVWLKDKSRATLFCLLDPTVLELRSSKMELFLSYWSGFIPHLNSLFHRAWDQSDVRALIEIFYVACD LHKWQFLSSCIDIFKESLEDQKATEEIVEFSFEDLGAFLFAIQSIFNKEDAEKIFVSNDQLSPILLVYIF DLFANRALLESQGEAIFQALDLIRSKVPENFYHDYLRNHEIRAHLWCRNEKALSTIFENYTEKQLKDEQH ELFVLYGCYLALIQGAEAAKQHFDVCREDRIFPASLLARNYNRLGLPKDALSYQERRLLLRQKFLYFHCL GNHDERDLCQTMYHLLTEEFQL Protective antigen IM-ID vaccination with CPn0095 (pknD) generated a response that resulted in moderately, but significantly reduced total C. pneumoniae lung loads as compared to control mice vaccinated with a plasmid expressing a non-Chlamydia ORF (p ≤ 0.019). This resulted in the ability of CPN0095 to mediate a moderate, but statistically significant level of protection in an inbred A/J mouse respiratory challenge model [Ref1063:Li et al., 2006]. Ssb Chlamydophila pneumoniae CWL029 VO_0010896 894901 15618301 CPn0386 AE001363 NP_224586 115713 434042 434524 - single-stranded DNA-binding protein 5.29 16434.22 160 binds to single stranded DNA and may facilitate the binding and interaction of other proteins to DNA >NC_000922.1:434042-434524 Chlamydophila pneumoniae CWL029 chromosome, complete genome ATTAAAAAGGAACATCTTCACAGACATACTGCTGTTCTTGACCATAACCAGCATACATATCTTTATCTTT AATAGCTTCTGCGTCCAGTGCTTCACCTTCAAACCCTACGGATACAGATTCATATCCCACTTGCTGATGA TTGTCTTCTAAAGATGGAGAACGGCTGCCTTCATTGCGACCGAAAGGACTGAATTTCAAAGAATCTACAC TAATCACTAAAGAAGATTGCGGTGAACCATCTTTGCTCATGTAACTCTCTACAGAGATATCGCCAGCAAC AATGACTCCTGAGCCTTTCTTCAAGTAAGGAAGCATCTTATCATAGCGATTGTGCCAAATATTGCATTTG CACCAAACAGTTTCATCTTTCATTCCAACTCGAGTCTTCACTCCCAGTCTCAGAGTGATCACACGTTTTC CTTTGGAAGTCATTCGCTCTTCAGGATCTGCTCCAAGGTAACCAGCAAAATGCCCAAACATCA >NP_224586.1 single-stranded DNA-binding protein [Chlamydia pneumoniae CWL029] MMFGHFAGYLGADPEERMTSKGKRVITLRLGVKTRVGMKDETVWCKCNIWHNRYDKMLPYLKKGSGVIVA GDISVESYMSKDGSPQSSLVISVDSLKFSPFGRNEGSRSPSLEDNHQQVGYESVSVGFEGEALDAEAIKD KDMYAGYGQEQQYVCEDVPF Protective antigen Mice vaccinated with candidate gene ssb showed significant reduction of spleen chlamydial loads as compared to naïve, non-protected control mice (p ≤ 0.048). This resulted in the ability of ssb to mediate a modest, but significant level of protection in an inbred A/J mouse respiratory challenge model [Ref1063:Li et al., 2006]. Atanu et al., 2013 journal Atanu FO, Oviedo-Orta E, Watson KA 2013 8 4 e61139 PloS one Faludi and Szabó, 2011 journal Faludi I, Szabó ÁM 2011 58 2 123-134 Acta microbiologica et immunologica Hungarica Faludi et al., 2009 journal Faludi I, Burian K, Csanadi A, Miczak A, Lu X, Kakkar VV, Gonczol E, Endresz V 2009 299 7 520-528 International journal of medical microbiology : IJMM Finco et al., 2005 journal Finco O, Bonci A, Agnusdei M, Scarselli M, Petracca R, Norais N, Ferrari G, Garaguso I, Donati M, Sambri V, Cevenini R, Ratti G, Grandi G 2005 23 9 1178-1188 Vaccine Li et al., 2006 journal Li D, Borovkov A, Vaglenov A, Wang C, Kim T, Gao D, Sykes KF, Kaltenboeck B 2006 24 15 2917-2927 Vaccine Lu et al., 2012 journal Lu X, Xia M, Endresz V, Faludi I, Szabo A, Gonczol E, Mundkur L, Chen D, Kakkar V 2012 225 1 56-68 Atherosclerosis Penttilä et al., 2000 journal Penttilä T, Vuola JM, Puurula V, Anttila M, Sarvas M, Rautonen N, Mäkelä PH, Puolakkainen M 2000 19 9-10 1256-1265 Vaccine Svanholm et al., 2000 journal Svanholm C, Bandholtz L, Castaños-Velez E, Wigzell H, Rottenberg ME 2000 51 4 345-353 Scandinavian journal of immunology Tammiruusu et al., 2007 journal Tammiruusu A, Penttilä T, Lahesmaa R, Sarvas M, Puolakkainen M, Vuola JM 2007 25 2 283-290 Vaccine Tammiruusu et al., 2007 journal Tammiruusu A, Penttilä T, Lahesmaa R, Sarvas M, Puolakkainen M, Vuola JM 2007 25 2 283-290 Vaccine Wiki: Chlamydophila pneumoniae website http://en.wikipedia.org/wiki/Chlamydophila_pneumoniae